Cord Blood Stem Cells and Regenerative Medicine discusses the current applications for cord blood stem cells and techniques for banking cord blood. Cord blood, blood from the umbilical cord and placenta of an infant, represents an alternate source of stem cells that can be used to treat a myriad of disorders. Cord blood stem cells are being used more frequently and studied more seriously, as evidenced by the explosion of scientific literature on the topic. Currently, clinical and pre-clinical trials are being done in the field, treating conditions as severe as heart failure. Coupled with regenerative medicine, cord blood stem cells potentially carry the future of research and medicine in treating tissue damage, genetic disorders, and degenerative diseases. Read about new applications for cord blood stem cells and new techniques for banking cord blood — the future of regenerative medicine therapy. Comprehensive coverage of the medical application of cord blood stem cells Practical guide for usage of allogeneic and autologous cord blood in regenerative medicine Covers new applications of cord blood stem cells, particularly transplantation and HIV Introduces new technologies for cord blood stem cells and regenerative medicine
With the potential for self-renewal and differentiation, the possibilities for stem cells are enormous. One specific type of stem cell, the hematopoietic progenitor cell (HPC), which is derived from umbilical cord blood (as well as adult bone marrow and mobilized peripheral blood), holds particular promise. To make the most of these HPCs, the Institute of Medicine was asked to consider the optimal structure for a national cord blood program and to address pertinent issues related to maximizing the potential of stem cell technology. Cord Blood: Establishing a National Hematopoietic Stem Cell Bank Program examines: The role of cord blood in stem cell transplantation The current status of blood banks already in existence The optimal structure for the cord blood program The current use and utility of cord blood for stem cell transplants The best way to advance the use of cord blood units and make them available for research Expert advice from leaders in the fields of economics, public health, medicine, and biostatistics combine to make this very timely and topical book useful to a number of stakeholders.
|Author||: Ana Colette Maurício|
|Publisher||: BoD – Books on Demand|
|Release Date||: 2017-01-11|
|ISBN 10||: 9535128655|
|Pages||: 258 pages|
Umbilical cord blood (UCB) and, more recently, umbilical cord tissue (UCT) have been stored cryopreserved in private and public cord blood and tissue banks worldwide, since the umbilical cord blood was used for the first time in a child with Fanconi anemia with his HLA-identical sibling, following strict guidelines that imply high-quality standards and total rastreability of these units. The hematopoietic stem cells (HSCs) are clinically used in hematopoietic treatments for blood disorders and hemato-oncological diseases. Also, the mesenchymal stem cells (MSCs) isolated from the UCT and UCB, nowadays, can be used as coadjuvants of hematopoietic transplants. In the near future, these stem cells will have a crucial role in regenerative medicine. For this reason, these cells have been tested in several clinical trials and compassive treatments in children and adults, concerning a wide range of pathologies and diseases, for instance, for the treatment of cerebral paralysis. Considering the worldwide availability of UCB and UCT units and the absence of ethical concerns will probably become the best sources for cell-based therapies for hematological and nonhematological pathologies. The UCB will also have a crucial role in neonatology-predictive analysis in the near future.
This comprehensive volume discusses the current scope of umbilical cord blood transplantation (UCBT), including recent controversies and future developments for improving clinical outcomes. Its twenty chapters introduce new applications in regenerative medicine and discuss the latest scientific, regulatory, clinical and investigational aspects of cord blood banking. Physicians from around the world provide a global collaboration which explores strategies for umbilical cord blood expansion, homing, unit selection, and combining of graft sources to improve patient outcomes. Umbilical Cord Blood Banking and Transplantation also reviews advances in pediatric UCBT for hematologic and non-hematologic disorders as well as immune recovery, which is critical to preventing infection. Finally, it compares UCBT with other graft sources in an attempt to understand the optimal graft source for the individual patient. UCBT is an important option for many patients who need a transplant but do not have a family donor or a matched unrelated donor. The collective and timely knowledge presented here is essential reading for any regenerative medicine investigator, cord blood banker, transplant laboratory scientist or clinical physician interested in improving and expanding the applications of umbilical cord blood.
|Author||: David S. Allan,Dirk Strunk|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2011-11-16|
|ISBN 10||: 9781617794711|
|Pages||: 220 pages|
Blood has long been viewed as a conduit for therapy, stemming from the ancient days of phlebotomy to remove evil humors to the development of successful blood transfusions to replace missing blood components. The identification and characterization of hematopoietic stem cells by Drs. Till and McCulloch revolutionized the field and soon after, non-hematopoietic stem and progenitor cells were characterized from the blood and bone marrow. Some of these cell types and various blood-derived cell lineages are involved in the repair of various types of tissue damage that span the spectrum of medical disorders. The goal of this book is to provide an up-to-date review of the various types of blood-derived cells with regenerative capacity, identify opportunities for intervention by examining specific clinical applications, and recognize the regulatory environment that will encompass future therapies in regenerative medicine.
Perinatal Stem Cells provides researchers and clinicians with a comprehensive description of the current clinical and pre-clinical applications of stem cells derived from perinatal sources, such as amniotic fluid, placenta and placental membranes, the umbilical cord and Wharton’s jelly. It's compiled by leading experts in the field, offering readers detailed insights into sources of perinatal stem cells and their potential for disease treatment. Therapeutic applications of perinatal stem cells include the treatment of in utero and pregnancy related diseases, cardiac disease, liver disease, pulmonary disease, inflammatory diseases, for hematopoietic regeneration, and for neural protection after stroke or traumatic brain injury. In addition, the rapid advance in clinical translation and commercialization of perinatal stem cell therapies is highlighted in a section on Clinical and Industry Perspective which provides insight into the new opportunities and challenges involved in this novel and exciting industry. Explores current clinical and pre-clinical application of stem cells derived from perinatal sources Offers detailed insight into sources of perinatal stem cells and their potential for disease treatment Discusses progress in the manufacturing, banking and clinical translation of perinatal stem cells Edited by a world-renowned team to present a complete story of the development and promise of perinatal stem cells
Umbilical cord blood, previously discarded after birth, has emerged over recent years as an alternative source of hematopoietic stem cells for hematological reconstitution, mainly for leukemia patients, as well as for some hematological deficiencies and bone marrow failures. In recent years, it has become increasingly clear that cord blood, as well as the surrounding tissue of the umbilical cord, contain additional stem cells which have been shown to be of great potential for regenerative medicine. Importantly, cord blood is abundant, it can be banked and shipped with ease, and thus has an indisputable potential for future medicines and regenerative therapies. Driven by a massive interest for regenerative medicine and alternative yet ethically acceptable stem cell sources, the scientific literature on umbilical cord and cord blood stem cells has increased tremendously. This book provides a consolidated, up-to-date overview of basic research on hematopoietic and mesenchymal stem cells contained within umbilical cord tissue, as well as other more recently described stem and precursor cells of not yet fully elucidated potential. It also takes an in-depth look at basic and translational research efforts with stem cells from the umbilical cord in academic institutions and biotech companies. Suitable for use as a primer and reference book by medical fellows and researchers entering the research fields of stem cell biology and regenerative medicine, it can also be used by students (undergraduate and graduate) as a starting point for read-up on the literature on stem cells and their potential and applications, or as a teaching tool in graduate schools for biologists, particularly for students wanting to enter the emerging field of stem cell biology.
Cord blood is a significant source of hematopoietic stem and progenitor cells for the treatment of blood and genetic disorders. Cord blood is also an alternative to embryos as a source of tissue for regenerative medicine. Cells from cord blood have been shown to transdifferentiate into nonhematopoietic cells, including those of the brain, heart, liver, pancreas, bone, and cartilage, in tissue culture and in animal systems. Recently it has been demonstrated that both cardiac and glial cell differentiation of cord blood donor cells occurred in recipients of unrelated donor cord blood transplantation as part of a treatment regime for Krabbe disease and Sanfilippo syndrome. These observations raise the possibility that cord blood may serve as a source of cells to facilitate tissue repair and regeneration in the future. CD34 stem cell-rich umbilical cord whole blood transfusion has the potential to have an immediate benefit of better tissue oxygenation with an additional delayed benefit of possible engraftment of umbilical cord stem cells.
This Volume of the series Cardiac and Vascular Biology offers a comprehensive and exciting, state-of-the-art work on the current options and potentials of cardiac regeneration and repair. Several techniques and approaches have been developed for heart failure repair: direct injection of cells, programming of scar tissue into functional myocardium, and tissue-engineered heart muscle support. The book introduces the rationale for these different approaches in cell-based heart regeneration and discusses the most important considerations for clinical translation. Expert authors discuss when, why, and how heart muscle can be salvaged. The book represents a valuable resource for stem cell researchers, cardiologists, bioengineers, and biomedical scientists studying cardiac function and regeneration.
|Author||: Anthony Atala|
|Release Date||: 2012-03-15|
|ISBN 10||: 0857096079|
|Pages||: 568 pages|
Progenitor and stem cells have the ability to renew themselves and change into a variety of specialised types, making them ideal materials for therapy and regenerative medicine. Progenitor and stem cell technologies and therapies reviews the range of progenitor and stem cells available and their therapeutic application. Part one reviews basic principles for the culture of stem cells before discussing technologies for particular cell types. These include human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells. Part two discusses wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies. The final part of the book considers the therapeutic use of stem and progenitor cells. Chapters review the use of adipose tissue-derived stem cells, umbilical cord blood (UCB) stem cells, bone marrow, auditory and oral cavity stem cells. Other chapters cover the use of stem cells in therapies in various clinical areas, including lung, cartilage, urologic, nerve and cardiac repair. With its distinguished editor and international team of contributors, Progenitor and stem cell technologies and therapies is a standard reference for both those researching in cell and tissue biology and engineering as well as medical practitioners investigating the therapeutic use of this important technology. Reviews the range of progenitor and stem cells available and outlines their therapeutic application Examines the basic principles for the culture of stem cells before discussing technologies for particular cell types, including human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells Includes a discussion of wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies
Examines the potential for stem cells gleaned from umbilical cords to generate a wealth of new therapy and healing medicines for neurological conditions and blood problems.
The book reviews the main approaches for generation of differentiated cells from various types of stem cells, including embryonic, placental and cord blood stem cells through marrow, adipose tissue and dental pulp. The book starts with an overview of experimental protocols applied to generate insulin secreting cells, neural cells, heart cells, and other tissue specific cells ex vivo and in experimental animals. This is followed by exhaustive review of clinical trials in these pathologies. It continues with a comparison of the merits of successful transplantation in humans versus animal experimentation, and highlights the most promising clinical applications in the field. Special chapters are devoted to the topic of tissue engineering and modern synthetic and biological scaffolds. It is essential reading for scientists and researchers in tissue engineering and stem cell research as well as clinicians who are involved in developing or testing stem cell therapies.